Literature DB >> 7943172

The cell type-specific IGF2 expression during early human development correlates to the pattern of overgrowth and neoplasia in the Beckwith-Wiedemann syndrome.

F Hedborg1, L Holmgren, B Sandstedt, R Ohlsson.   

Abstract

Overstimulation by insulin-like growth factor II is implied in several overgrowth conditions and childhood cancers. We have therefore studied spatial and temporal expression patterns of the insulin-like growth factor II gene (IGF2) and the insulin-like growth factor type 1 receptor gene during normal human development (5.5 to 23.0 weeks postfertilization). The set of cell types with the most abundant IGF2 expression correlated strikingly to the organomegaly and tumor predisposition of the Beckwith-Wiedemann syndrome. Intrauterine growth and postnatal organ weights of a prematurely born child with a full-blown syndrome are presented. The cell type-specific IGF2 expression of these organs and of multifocal Wilms' tumors from two other children affected by the Beckwith-Wiedemann syndrome were also studied. The results clarify and extend previous findings concerning human prenatal IGF2 expression and are consistent with a short range overstimulatory role of locally produced IGF II ensuing after the first trimester in the Beckwith-Wiedemann syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943172      PMCID: PMC1887333     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

Review 1.  The chromaffin and chromaffin-like cells in the autonomic nervous system.

Authors:  J Taxi
Journal:  Int Rev Cytol       Date:  1979

2.  Beckwith-Wiedemann syndrome. Wilms' tumor, cardiac hamartoma, persistent visceromegaly, and glomeruloneogenesis in a 2-year-old boy.

Authors:  J K Reddy; R N Schimke; C H Chang; D J Svoboda; J Slaven; L Therou
Journal:  Arch Pathol       Date:  1972-12

3.  Beckwith's syndrome with extreme organ hyperplasia.

Authors:  T F Roe; A K Kershnar; J J Weitzman; L S Madrigal
Journal:  Pediatrics       Date:  1973-09       Impact factor: 7.124

4.  Exomphalos with macroglossia: a study of eleven cases.

Authors:  I M Irving
Journal:  J Pediatr Surg       Date:  1967-12       Impact factor: 2.545

5.  The placenta in familial beckwith-wiedemann syndrome.

Authors:  L R Shapiro; P A Duncan; M M Davidian; N Singer
Journal:  Birth Defects Orig Artic Ser       Date:  1982

6.  Neuroblastoma associated with Beckwith-Wiedemann syndrome.

Authors:  L G Emery; M Shields; N R Shah; A Garbes
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

7.  Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential.

Authors:  C Sotelo-Avila; F Gonzalez-Crussi; J W Fowler
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

8.  Relaxation of imprinted genes in human cancer.

Authors:  S Rainier; L A Johnson; C J Dobry; A J Ping; P E Grundy; A P Feinberg
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

9.  Cardiovascular abnormalities in the Beckwith-Wiedemann syndrome.

Authors:  R D Greenwood; A Somer; A Rosenthal; J Craenen; A S Nadas
Journal:  Am J Dis Child       Date:  1977-03

10.  A variant of the Wiedemann-Beckwith syndrome.

Authors:  W Wöckel; K Scheibner; A Lageman
Journal:  Eur J Pediatr       Date:  1981-02       Impact factor: 3.183

View more
  12 in total

Review 1.  Maternal-placental-fetal interactions in the endocrine regulation of fetal growth: role of somatotrophic axes.

Authors:  Peter D Gluckman; Catherine S Pinal
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Is p57KIP2 mutation a common mechanism for Beckwith-Wiedemann syndrome or somatic overgrowth?

Authors:  K Okamoto; I M Morison; A E Reeve; N Tommerup; H R Wiedemann; U Friedrich
Journal:  J Med Genet       Date:  1998-01       Impact factor: 6.318

3.  Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells.

Authors:  C J Kim; T Matsuo; K H Lee; C J Thiele
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 4.  Cell signaling pathways in the adrenal cortex: Links to stem/progenitor biology and neoplasia.

Authors:  Morgan K Penny; Isabella Finco; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2016-12-08       Impact factor: 4.102

5.  Differentiation in neuroblastoma: diffusion-limited hypoxia induces neuro-endocrine secretory protein 55 and other markers of a chromaffin phenotype.

Authors:  Fredrik Hedborg; Reiner Fischer-Colbrie; Nurtena Ostlin; Bengt Sandstedt; Maxine G B Tran; Patrick H Maxwell
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

6.  IGF2 expression is a marker for paraganglionic/SIF cell differentiation in neuroblastoma.

Authors:  F Hedborg; R Ohlsson; B Sandstedt; L Grimelius; J C Hoehner; S Pählman
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

7.  Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors.

Authors:  Michael R Sprehe; Nadia Barahmani; Yumei Cao; Tao Wang; Michele R Forman; Melissa Bondy; M Fatih Okcu
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

8.  Adrenal Medullary Nodules in Beckwith-Wiedemann Syndrome Resemble Extra-Adrenal Paraganglia.

Authors:  Arthur S. Tischler; Joseph Semple
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

9.  The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

Authors:  Alessandro Mussa; Kelly A Duffy; Diana Carli; Jessica R Griff; Riccardo Fagiano; Jonida Kupa; Garrett M Brodeur; Giovanni Battista Ferrero; Jennifer M Kalish
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-04       Impact factor: 4.553

Review 10.  The new dysmorphology: application of insights from basic developmental biology to the understanding of human birth defects.

Authors:  C J Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.